FCA
MRNA icon

FinTrust Capital Advisors’s Moderna MRNA Stock Holding History

FinTrust Capital Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$201 Sell
3
-73
-96% -$6.7K ﹤0.01% 1341
2024
Q2 		$9.03K Buy
76
+27
+55% +$3.42K ﹤0.01% 922
2024
Q1 		$5.22K Hold
49
– – ﹤0.01% 985
2023
Q4 		$4.87K Sell
49
-125
-72% -$10.5K ﹤0.01% 968
2023
Q3 		$18K Buy
174
+111
+176% +$12.4K ﹤0.01% 678
2023
Q2 		$11.3K Hold
63
– – ﹤0.01% 747
2023
Q1 		$11.3K Hold
63
– – ﹤0.01% 745
2022
Q4 		$11.3K Hold
63
– – ﹤0.01% 742
2022
Q3 		$8K Sell
63
-125
-66% -$19K ﹤0.01% 933
2022
Q2 		$31K Buy
188
+166
+755% +$23.7K 0.01% 622
2022
Q1 		$4K Sell
22
-105
-83% -$17.7K ﹤0.01% 1099
2021
Q4 		$32K Sell
127
-184
-59% -$53.8K 0.01% 626
2021
Q3 		$120K Buy
311
+17
+6% +$6.27K 0.03% 371
2021
Q2 		$69K Hold
294
– – 0.02% 505
2021
Q1 		$38K Sell
294
-100
-25% -$14.5K 0.01% 577
2020
Q4 		$41K Buy
394
+194
+97% +$19.6K 0.01% 531
2020
Q3 		$14 Buy
200
+46
+30% +$3.21K ﹤0.01% 724
2020
Q2 		$10K Buy
154
+19
+14% +$1.04K ﹤0.01% 730
2020
Q1 		$4K Buy
+135
New +$3.11K ﹤0.01% 910

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FinTrust Capital Advisors's MRNA Position: Q3 2024 in Review

FinTrust Capital Advisors reduced its Moderna (MRNA) stake by 96% in Q3 2024, selling an estimated $6.7K and leaving 3 shares worth $201. The position accounts for ﹤0.01% of the portfolio, ranked #1341.

FinTrust Capital Advisors first reported a position in MRNA in Q1 2020 and has held it in 19 quarters since. The position peaked at $120K in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • FinTrust Capital Advisors held 3 shares of Moderna worth $201 as of Q3 2024.
  • FinTrust Capital Advisors sold 73 Moderna shares in Q3 2024, an estimated $6.7K.
  • Moderna made up ﹤0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #1341 holding.
  • FinTrust Capital Advisors first reported a position in Moderna in Q1 2020 and has held it in 19 quarters since.
  • FinTrust Capital Advisors's Moderna position peaked at $120K in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.